For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

We all react to environmental cues that tell us it’s time to eat, like the scent of fries wafting through the air. These cues ...

(Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) For those who are overweight or obese, medications known as glucagon-like peptide-1 agonists, or GLP-1s, have become very ...

Savannah Mendoza used to spend most of her paychecks on food delivery apps and at fast food drive-thrus, trying to satisfy a ...

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of hospital readmission, wound re-opening and hematoma after surgery ...

Between Novo Nordisk's (NVO) slightly disappointing results for its latest GLP-1 candidate, CagriSema, and questions that remain about Amgen's (AMGN) highly anticipated once-monthly injectable ...